PATIENT-CENTRIC REQUIREMENTS FOR THE SUPPLY OF RAW MATERIALS INTO BIOPHARMACEUTICAL MANUFACTURING by magma | Jun 13, 2016 | Drug Substance News, White Papers | 1 comment To download your free copy of the paper, please complete this registration form so that we know who is interested in this topic. You will be linked immediately to the RMV Paper. Raw material variability and control of the supply chain are important issues for the biopharmaceutical industry. The industry is still at an early stage in the journey to align the supply base with biopharma’s requirements to improve patient well-being by assuring product safety and meeting ever-increasing regulatory demands. This requires increased understanding, monitoring and control of raw materials. Leading global Biopharmaceutical Manufacturers have been working together within the Biophorum Operations Group (BPOG) and collaborating to create an industry endorsed and supported guidance package. LoginRegister Now[profilepress-login id="8" redirect="https://www.biophorum.com/patient-centric-requirements-for-the-supply-of-raw-materials-into-biopharmaceutical-manufacturing/"][profilepress-registration id="6" redirect="https://www.biophorum.com/patient-centric-requirements-for-the-supply-of-raw-materials-into-biopharmaceutical-manufacturing/"] 1 Comment Michael Sunkin on 29th August 2017 at 4:11 pm This is a really great paper, I wonder if there are more components other than peptone that are risk prone in the biopharm industry. It would be nice to present these needs to key biopharm suppliers or research groups so they they can develop products and technologies to fit those industry risks. Reply Submit a Comment Cancel reply Your e-mail address will not be published. Required fields are marked *Comment Name * Email * Website Save my name, e-mail, and website in this browser for the next time I comment. This site uses Akismet to reduce spam. Learn how your comment data is processed.